ICON plc to Present at the Jefferies Virtual Healthcare Conference and the William Blair 41st Growth Stock Conference
2021年5月25日 - 7:00PM
ビジネスワイヤ(英語)
ICON plc, (NASDAQ: ICLR) a global provider of outsourced drug
and device development and commercialisation services to
pharmaceutical, biotechnology, medical device and government and
public health organisations, today announced that Mr. Brendan
Brennan, CFO of ICON plc, will present at the Jefferies Virtual
Healthcare Conference on Tuesday, June 1, 2021. The presentation
will be webcast live from 08.00am ET. It was also announced that
Dr. Steve Cutler, CEO of ICON plc, will present at the William
Blair 41st Growth Stock Conference on Wednesday, June 2, 2021. The
presentation will be webcast live from 11.40am ET.
Any changes to these events and links to the live webcasts
(where available) will be posted on the Investor section of our
website under “Events”.
About ICON plc
ICON plc is a global provider of outsourced drug and device
development and commercialisation services to pharmaceutical,
biotechnology, medical device and government and public health
organisations. The company specialises in the strategic
development, management and analysis of programs that support
clinical development - from compound selection to Phase I-IV
clinical studies. With headquarters in Dublin, Ireland, ICON
employed approximately 16,070 employees in 89 locations in 43
countries as at March 31, 2021. For further information about ICON,
visit: www.iconplc.com and www.iconplc.com/pra.
This press release contains forward-looking statements. These
statements are based on management's current expectations and
information currently available, including current economic and
industry conditions. These statements are not guarantees of future
performance or actual results, and actual results, developments and
business decisions may differ from those stated in this press
release. The forward-looking statements are subject to future
events, risks, uncertainties and other factors that could cause
actual results to differ materially from those projected in the
statements, including, but not limited to, the ability to enter
into new contracts, maintain client relationships, manage the
opening of new offices and offering of new services, the
integration of new business mergers and acquisitions, the impact of
COVID-19 on our business, as well as other economic and global
market conditions and other risks and uncertainties detailed from
time to time in SEC reports filed by ICON, all of which are
difficult to predict and some of which are beyond our control. For
these reasons, you should not place undue reliance on these
forward-looking statements when making investment decisions. The
word "expected" and variations of such words and similar
expressions are intended to identify forward-looking statements.
Forward-looking statements are only as of the date they are made
and we do not undertake any obligation to update publicly any
forward-looking statement, either as a result of new information,
future events or otherwise. More information about the risks and
uncertainties relating to these forward-looking statements may be
found in SEC reports filed by ICON, including its Form 20-F, F-1,
S-8 and F-3, which are available on the SEC's website at
http://www.sec.gov.
As announced on February 24th, 2021, ICON and PRA Health
Sciences (“PRA”) have entered into a definitive merger agreement.
This communication does not constitute an offer to sell or buy or
the solicitation of any offer to buy or sell any securities, nor
shall there be any sale of securities in a jurisdiction in which
such offer, solicitation, or sale would be unlawful prior to
registration or qualification under the securities law of any such
jurisdiction. No offering of securities shall be made except by
means of a prospectus meeting regulatory requirements of Section 10
of the Securities Act of 1933. In connection with the proposed
transaction, ICON has filed a registration statement on Form F-4
(File No. 333-254891) with the SEC containing a prospectus of ICON
that also constitutes a proxy statement of each of ICON and
PRA.
This communication is not a substitute for the joint proxy
statement/prospectus or registration statement or for any other
document that ICON or PRA have filed or may file with the SEC in
connection with the potential transaction. INVESTORS AND SECURITY
HOLDERS OF ICON AND PRA ARE URGED TO READ THE JOINT PROXY
STATEMENT/PROSPECTUS AND OTHER DOCUMENTS THAT ARE FILED OR WILL BE
FILED WITH THE SEC, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO
THESE DOCUMENTS, CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME
AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION.
Investors and security holders will be able to obtain free copies
of the joint proxy statement/prospectus and other documents filed
with the SEC by ICON or PRA through the website maintained by the
SEC at http://www.sec.gov. Copies of the documents filed with the
SEC by ICON will be available free of charge on ICON’s website at
https://www.iconplc.com and copies of the documents filed with the
SEC by PRA will be available free of charge on PRA’s website at
https://www.prahs.com/. Additionally, copies may be obtained by
contacting the investor relations departments of ICON or PRA.
ICON and PRA and certain of their respective directors, certain
of their respective executive officers and other members of
management and employees may be considered participants in the
solicitation of proxies with respect to the potential transaction
under the rules of the SEC. Information about the directors and
executive officers of ICON is set forth in its annual report on
Form 20-F, which was filed with the SEC on February 24, 2021.
Information about the directors and executive officers of PRA is
set forth in its Amendment to Annual Report on Form 10-K/A for the
fiscal year ended December 31, 2020, which was filed with the SEC
on March 30, 2021. These documents can be obtained free of charge
from the sources indicated above. Additional information regarding
the interests of such participants in the solicitation of proxies
in respect of the potential transaction are included in the
registration statement and joint proxy statement/prospectus and
other relevant materials filed with the SEC.
ICON/ICLR-G
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210525005450/en/
Investor Relations +1888 381 7923
Jonathan Curtain Vice President Corporate Finance and Investor
Relations +353 1 291 2000
ICON (NASDAQ:ICLR)
過去 株価チャート
から 9 2024 まで 10 2024
ICON (NASDAQ:ICLR)
過去 株価チャート
から 10 2023 まで 10 2024